CSTL
Castle Biosciences, Inc.
CSTL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
CSTL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CSTL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
CSTL PE Valuation
CSTL has no meaningful PE right now: it lost money over the past year.
CSTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CSTL's losses to shrink, with revenue growing.
CSTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.75 | -$0.30 |
| Q2 2026 | -$0.64 | -$0.29 |
| Q1 2026 | -$0.42 | -$0.23 |
| Q4 2025 | -$0.83 | -234% |
| Q3 2025 | -$0.45 | -305% |
| Q2 2025 | -$0.35 | -$0.23 |
| Q1 2025 | -$0.19 | +$0.94 |
| Q4 2024 | $0.62 | +$2.76 |
CSTL is still losing money, but far less than before: $0.75 per share over the past year, against $3.35 at its worst in mid-2023.
CSTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.9M | +24% |
| Q2 2026 | $103.5M | +20% |
| Q1 2026 | $83.7M | -4.9% |
| Q4 2025 | $87M | +0.8% |
| Q3 2025 | $83M | -3.2% |
| Q2 2025 | $86.2M | -0.9% |
| Q1 2025 | $88M | +21% |
| Q4 2024 | $86.3M | +31% |
CSTL's revenue is growing: $103M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.6% | +5.5 points |
| Q2 2026 | -3% | +2 points |
| Q1 2026 | -22% | +9.7 points |
| Q4 2025 | -4.4% | -9.1 points |
| Q3 2025 | -8.2% | -14 points |
| Q2 2025 | -4.9% | -11 points |
| Q1 2025 | -32% | -24 points |
| Q4 2024 | 4.7% | +13 points |
CSTL's operating margin was −2.6% last quarter, up 5.5 points from the same quarter a year ago.
CSTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.2M | +57% |
| Q2 2026 | $6.6M | -43% |
| Q1 2026 | -$34.6M | -$23.8M |
| Q4 2025 | $19.7M | +18% |
| Q3 2025 | $7.8M | -54% |
| Q2 2025 | $11.6M | -38% |
| Q1 2025 | -$10.8M | +$5.2M |
| Q4 2024 | $16.8M | +14% |
CSTL still generates free cash flow, though less than at its 2025 peak: $4M over the past year.
CSTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +234K shares |
| 1 year | +5.4% | +1.6M shares |
| 3 years | +14% | +3.8M shares |
| 5 years | +21% | +5.3M shares |
| Available history | +64% | +11.9M shares |
CSTL has 31M diluted shares, up 5.4% from a year ago.
CSTL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
| Q2 2025 | -3.7x | Net Cash |
| Q1 2025 | -2.8x | Net Cash |
| Q4 2024 | -4.5x | Net Cash |
| Q3 2024 | -6.8x | Net Cash |
| Q2 2020 | -19.8x | Net Cash |
| Q1 2020 | -8.1x | Net Cash |
| Q4 2019 | -9.6x | Net Cash |
CSTL has more cash than debt.
CSTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 63.5 | Neutral |
CSTL's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
CSTL PE vs Healthcare Sector
| Metric | CSTL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSTL has no meaningful PE right now: it lost money over the past year.
CSTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.4 | 0.3% above |
| 20 week MA | $31.5 | 9.6% above |
| 50 week MA | $30.0 | 15% above |
| 100 week MA | $26.4 | 31% above |
| 200 week MA | $24.4 | 41% above |
CSTL is in an uptrend: it's above all five of its weekly moving averages, and 41% above its 200-week average.
CSTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.0 | $71.3 | +110% |
| 2021 | $71.3 | $42.6 | -40% |
| 2022 | $42.6 | $23.2 | -45% |
| 2023 | $23.2 | $21.6 | -7.1% |
| 2024 | $21.6 | $26.8 | +24% |
| 2025 | $26.8 | $39.4 | +47% |
| 2026 YTD | $39.4 | $34.5 | -12% |
CSTL's yearly returns have swung widely, from +110% in 2020 to −45% in 2022. It's down 12% so far in 2026.